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Abstract
Rationale: Follicular non-Hodgkin lymphoma (fNHL) is a neoplasm characterized by an indolent course and chemosensitivity, but
also by disease recurrence. Bendamustine is often used as frontline treatment or second line.
Heading diagnosis: fNHL.
Patient concerns: A 63-year-old Caucasian male with diagnosis of fNHL lymphoma underwent to cyclophosphamide,
doxorubicin, vincristine, and prednisone associated with rituximab chemoimmunotherapy, during which interim reevaluation showed
progressive disease and severe toxicity.
Interventions: Early switch to rituximab-bendamustine.
Outcomes: This regimen was well tolerated, patient compliance was optimal, there were no delays in administration and no
infectious episodes. An interim reevaluation after 3 courses revealed that the patient was fit, the blood cell count was normal, and
lymphadenopathies and nocturnal sweating had completely regressed. Of note, the PET/CT scan did not show fluorodeoxyglucose
pathological uptake, clearly confirming disease regression.
Lessons: Early switching to a bendamustine-rituximab-based scheme, even during conventional chemotherapy, decreases
toxicity and reduces the risk of treatment interruption or delay, with favorable effects on overall response and prognosis.
Abbreviations: CHOP = cyclophosphamide, doxorubicin, vincristine and prednisone, fNHL = follicular non-Hodgkin lymphoma,
R-CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone associated with rituximab.
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Follicular non-Hodgkin lymphoma (fNHL) is the most common
type of non-Hodgkin lymphoma in the United States and Europe.
It is a heterogeneous group of indolent and slow-growing
neoplasms which, although showing significant chemosensitivityEditor: Maya Saranathan.
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to conventional frontline treatments, are characterized by
recurrence. Themost widely used frontline chemotherapy scheme
is cyclophosphamide, doxorubicin, vincristine, and prednisone
(CHOP) associated with cyclophosphamide, doxorubicin, vin-
cristine, and prednisone associated with rituximab (R-CHOP),ion of Helsinki.
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during the current study.
RST) IRCCS, Meldola, b Department of Hematology and CBMT, Ospedale di
les, d Hematology Unit, Department of Clinical Medicine and Surgery, University
per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014
ense 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in
ane F, De Renzo A, Martinelli G. Can early switch to rituximab-bendamustine in a
red frontline treatment? A case report. Medicine 2020;99:33(e21440).
ne 2020
Cerchione et al. Medicine (2020) 99:33 Medicinebut rituximab-bendamustine has become an alternative frontline
option for many patients.[1] Italian and European guidelines for
second-line therapy consist in different options, among which
bendamustine can be used as a single agent or in combination
with others.[2,3] Here, we describe the case of a 63-year-old
patient with fNHL who was switched to rituximab-bendamus-
tine as early second-line treatment after 2 courses of R-CHOP,
interrupted because of hematological toxicity and signs of
progressive disease. This strategy resulted in complete disease
remission, highlighting the effectiveness of the early switch to a
bendamustine-based regimen, even during disease progression.2. Case presentation
A 63-year-old Caucasian male was referred to our Hematology
Unit because of multiple superficial lymphadenopathies, a 5-kg
weight loss in the previous 3 months, anorexia, itching, and
copious nocturnal sweating. The patient’s general conditions
were fairly good and his past medical history was negative.
Clinical examination confirmed several lymphadenopathies (up
to 3cm), mild hepatomegaly and notable splenomegaly (20cm).
A complete blood count revealed leukocytosis with lymphocyto-
sis and a blood smear showed small lymphocytes with thickened
chromatin and scant cytoplasm. Flow cytometric analysis was
positive for CD20, CD10, and CD5. An 18F-FDG (fluorodeox-
yglucose) PET/CT scan (Fig. 1) showed and accumulation of FDG
in several deep and superficial lymph node locations (standard-
ized uptake value (SUV) max range 2–7.7). Excisional biopsy of
the largest lymph node in the left axillary region led to a diagnosis
of fNHL, stage IV B, CD20+ and bcl-2+. The histological exam
showed substantial lymphocytic infiltration (about 82% of the
total cell population), while flow cytometry was positive for
CD19, CD20, CD10, and k-chains. Conventional frontline
treatment with the R-CHOP scheme (rituximab, cyclophospha-
mide, doxorubicin, vincristine, prednisone) was planned together
with supportive therapy consisting in growth factors (pegfil-Figure 1. Positron emission tomography/computed tomography scan at
diagnosis showed accumulation of fluorodeoxyglucose in several deep and
superficial lymph node locations (SUV max range 2–7.7).
2
grastim and erythropoietin b administered from the first cycle
onwards). The second course was deferred because of hemato-
logical adverse events, that is, common terminology criteria for
adverse events grade III anemia and febrile neutropenia, initially
treated with ciprofloxacin per os and then substituted with
ceftriaxone as fever persisted. After the third cycle of R-CHOP,
clinical and instrumental interim reevaluation showed progres-
sive disease. Systemic B-symptoms were still reported by the
patients and lymph-nodes were unmodified at clinical evaluation.
18F-FDG-PET/CT showed no substantially changes in lympha-
denomegaly volumes. The frontline regimen was thus interrupted
and switched to bendamustine-rituximab (rituximab 375mg/m2
on day 1 and bendamustine 90mg/m2 on days 1–2) supported by
growth factors (pegfilgrastim 6mg on day 4[4–9] and erythropoi-
etin b 30,000U/wk, administered from the first cycle onwards),
every 28 days for 6 courses. This regimen was well tolerated,
patient compliance was optimal, there were no delays in
administration and no infectious episodes. An interim reevalua-
tion after three courses revealed that the patient was fit, the blood
cell count was normal, and lymphadenopathies and nocturnal
sweating had completely regressed. Of note, the 18F-FDG PET/
CT scan did not show FDG pathological uptake, clearly
confirming disease regression (Fig. 2).
3. Discussion
R-CHOP is a consolidated chemotherapeutic scheme widely used
as frontline treatment for fNHL. There are several second-line
options for refractory or relapsed disease among which
bendamustine is utilized as a single or combined agent. OurFigure 2. Reevaluation positron emission tomography/computed tomography
scan revealed no fluorodeoxyglucose pathological accumulation, confirming
clear disease regression.
Cerchione et al. Medicine (2020) 99:33 www.md-journal.comdecision to suddenly switch to another chemotherapy regimen
was made by clinical findings (no response to frontline
treatment), data from literature and, finally, to our clinical
experience in mitigate side effects of bendamustine. Response
rates with bendamustine in refractory/relapsed patients after a
frontline therapy are excellent and well tolerated, with a 90%
overall response rate, a complete response rate of up to 69% and
progression-free survival of 23 months.[1,10–14]
The 2 regimens, R-CHOP and bendamustine-rituximab, were
directly compared by Rummel et al in a randomized trial
evaluating patients with indolent lymphomas, revealing an
advantage for the bendamustine-rituximab scheme in terms of
median progression-free survival (69.5 vs 31.2 months, respec-
tively) and tolerability (lower rates of grade 3–4 neutropenia in
the former).[15] Another study (BRIGHT trial) confirmed the
noninferiority of bendamustine over R-chemotherapy regimens
(R-CHOP, R-CVP (Rituximab- C – cyclophosphamide, V –
vincristine, P – prednisolone)) in terms of effectiveness as first-line
treatment in this setting.[16] Thus, despite the lack of difference in
long-term overall survival (OS), bendamustine would seem to be
a better choice for patients who are more likely to be susceptible
to the toxic effects of more intensive combination treatments such
as the elderly or those with numerous comorbidities.
During frontline therapy with R-CHOP, our patient experi-
enced substantial hematological toxicity resulting in severe
anemia and neutropenia, even though growth factors were used.
In particular, our group has previously demonstrated that
primary prophylaxis with pegfilgrastim during bendamustine-
containing therapy is more effective than secondary prophylaxis
with non-pegylated granulocyte colony-stimulating factors in
increasing tolerability and in helping to respect dose-density and
dose-intensity, regardless of the type, biology and clinical
behavior of the lymphoproliferative disease, for example,
lymphoma and multiple myeloma. Severe febrile neutropenia
was present, but the short duration and the relatively benign
course did not necessitate treatment disruption, allowing us to
switch to a more tolerable regimen for the patient.
There is still no clear evidence in the literature of the
effectiveness of early treatment switching in patients with
indolent lymphomas who relapse or experience severe toxicity
whilst undergoing R-CHOP. However, in our patient early
second-line treatment with rituximab-bendamustine was well
tolerated, obtaining results that make it a potentially effective
option for patients with early refractory or relapsed fNHL after
frontline therapy, or even for those progressing on conventional
chemotherapy. We conclude that early switching to a bend-
amustine-rituximab-based scheme, even during conventional
chemotherapy, decreases toxicity and reduces the risk of
treatment interruption or delay, with favorable effects on overall
response and prognosis.
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